Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-stage, Phase 1/2a Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (Phase 1)

NCT04699669 is registered in ClinicalTrials.gov with Caliway Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT04699669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04699669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-stage, Phase 1/2a Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (Phase 1)
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 27, 2018
Completion date
August 20, 2019
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

subcutaneous fat